Human tumor xenograft studies are the primary means to evaluate the biological activity of anticancer agents in latestage preclinical drug discovery. The variability in the growth rate of human tumors established in mice and the small sample sizes make rigorous statistical analysis critical. The most commonly used summary of antitumor activity for these studies is the T/C ratio. However, alternative methods based on growth rate modeling can be used. Here, we describe a summary metric called the ratebased T/C, derived by fitting each animal's tumor growth to a simple exponential model. The ratebased T/C uses all of the data, in contrast with the traditional T/C, which only uses a single measurement. We compare the ratebased T/C with the traditional T/C and assess their performance through a bootstrap analysis of 219 tumor xenograft studies. We find that the ratebased T/C requires fewer animals to achieve the same power as the traditional T/C. We also compare 14day studies with 21day studies and find that 14day studies are more cost efficient. Finally, we perform a power analysis to determine an appropriate sample size.
Introduction
Human tumor cell lines grown as xenografts in immuno compromised mice have in recent years played an increasingly important role in the latestage preclinical development of targeted anticancer therapies. [1] [2] [3] [4] [5] Identification of compounds and dose regimens with the broadest possible therapeutic win dow (the range between the maximal efficacy and the minimum allowable toxicity) is a driving goal of latestage preclinical research. Evaluating the ability of anticancer agents to reduce tumor growth in preclinical xenograft models provides the basis for compound optimization. Preclinical biological acti vity in xenograft models has been shown to be reasonably well correlated with human clinical outcomes, 6 particularly when conducted at clinically relevant exposures. 7 A typical xenograft study involves the comparison of different drug treatments or combinations of drugs in mice bearing xenograft tumors in their flanks. Therapy is typically initiated only after tumors have reached a certain minimum size. During this treatment phase, repeated measurements of the tumor volume are made using digital calipers, and bio logical activity is quantified via the assessment of changes in tumor volume between treated and control mice.
One common measure of efficacy is the T/C ratio, the ratio of tumor volume in control versus treated mice at a specified Growth Rate Analysis and Efficient Experimental Design for Tumor Xenograft Studies time. Another measure that is frequently used is the closely related Tumor Growth Inhibition index, which is defined as (1 -(mean volume of treated tumors)/(mean volume of control tumors)) × 100%. While these measures are easy to implement and interpret, they have their limitations. In particular, the measures are inefficient, as they do not make use of any data collected before the final day of treatment. Another problem is that the measure is biased because animals are usually sacri ficed when the tumor volume exceeds 10% of the body weight or exceeds 2 cm in diameter. If this occurs before the end of the study, these animals will be excluded from the analysis. A second source of bias occurs when tumors in the control group (which are usually larger than those in the treatment group) experience a differential slowing of their growth rate relative to treatment because of nutrient and oxygenlimiting conditions.
Various researchers have considered alternative methods of analyzing xenograft studies, and several complex models have been proposed that fit all the data. [8] [9] [10] [11] [12] [13] [14] Some of the methods are based on nonparametric analysis, 8, 9 which may not have sufficient power to handle small sample sizes. Other research ers have used mixedeffects regression models, [10] [11] [12] [13] [14] which pro vide several advantages, including the ability to model missing data, mousetomouse variability in the growth rates, and a correlated noise structure. However, the multiple coefficients of a nonlinear regression model are less interpretable than a single efficacy measure (analogous to a T/C ratio or a Tumor Growth Inhibition index). From an organizational standpoint, these complex models lie outside the domain of offtheshelf statistical methods, and are complicated to implement and understand from the biologists' perspective. The sheer volume of xenograft studies in even a midsized company may make customfit regression models for each study unrealistic.
In this paper, we present a new method of analysis called the ratebased T/C, which is based on fitting each tumor's growth curve to an exponential model. This approach makes use of all the available data, and it is simple enough to be calcu lated with an Excel spreadsheet. We verify that the ratebased T/C has better precision than the traditional T/C by applying both methods to data from a large number of inhouse studies. By making more efficient use of the data, the ratebased T/C may allow fewer animals to be used in the study while still maintaining sufficient precision.
In addition to the analysis method, we also consider aspects of the experimental design. In particular, we compare the cost effectiveness of 14day studies with 21day studies. We also show how historical datasets can be used to recom mend a sample size with adequate power for future studies. These findings should allow researchers to reduce study costs and obtain accurate estimates of in vivo biological activity.
Quick Guide to equations and Assumptions
We assume that the tumor volume for each animal follows an exponential growth pattern. This can be written as log ( ) 10 tumor volume time error = + × + a b
(1)
Here, a and b are parameters that correspond to the log initial volume and growth rate, respectively. These parame ters are specific to a given animal. We assume that the error terms are independent and normally distributed with equal variance.
We consider two measures of antitumor activity. The first is the traditional T/C (commonly used), which is defined as traditional / mean tumor volume in the treatment group T C = at the final day of treatment mean volume in the control g group at the final day of treatment
The second measure, proposed by us, is called the rate based T/C. This is based on the ratio of the fitted growth rates of treated versus control groups, normalized to a study length of 21 days.
Rate-based
Here, µ T is the mean of the growth rates for the treat ment group, and µ C is the mean of the growth rates for the control group. The ratebased T/C uses a fixed time (day 21) so that it is less dependent on the choice of the final treat ment day. A time of 21 days was chosen so as to be consis tent with the most commonly used treatment length at our facility.
To evaluate the precision of the ratebased T/C and the traditional T/C, we compare the Zscores of the two mea sures. The Zscore is computed by generating a large number of bootstrap samples 15 from the original data and computing the measures on each sample. For a given measure of antitumor activity, we define the Zscore as 16 Z-score mean across the bootstrap samples of the log of = t the measure standard deviation across the bootstrap samples s of the log of the measure
A larger Zscore indicates better precision for the mea sure. This formula assumes that the measure is always positive and that it equals one under the null hypothesis. The Zscore could be used to estimate the power to detect a significant dif ference between the two groups at a given false positive rate (α). We used the formula 17 Power score s core
Here, Φ is the cumulative distribution function of the standard normal distribution. This formula assumes that the distribution of the log of the measure across the bootstrap samples is approximately normal.
Materials and Methods
Xenograft studies. To assess the performance of differ ent measures and experimental designs, we retrospectively analyzed a set of 219 xenograft biological activity studies in mice completed between 2006 and 2012. The studies involved 36 different xenograft models derived from cell lines. Supple mentary Table S1 lists the number of studies completed with each of the different models. Thirteen different drug discovery programs spanning a variety of drug targets were used to pro vide a range of different cell lines and model systems for the exploration of the modelfitting procedures. Although each study is unique, the experimental details for a typical study in our analysis are described by Kupperman et al. 18 Our research made use of data collected for other purposes, and thus no additional animals were needed for our work. Therefore our research did not require IRB approval.
The average number of treatment groups was 4.4 (in addition to the control group), and a majority (76%) of the studies in this dataset had between two and six treatment groups. Most studies (78%) used 10 animals in each treat ment group, while a significant minority (7%) used 8 animals per group.
The average study length in this dataset was 21 days (SD = 5). Longer studies included a regrowth phase (following the final day of treatment). All studies were considered only during their treatment phase (some studies included a regrowth phase, which was not used in the analysis). Studies involving primary patientderived xenografts were not included in the analysis. For the purposes of this analysis, we did not include biological treatments, focusing exclusively on smallmolecule treatments. It is worth noting that biological treatments may behave differently in terms of growth kinetics.
tumor volume measurements. The width and length of the tumors were measured at regular intervals (typically twice weekly) with digital vernier calipers. The volumes were estimated using the formula: volume = (width) 2 × (length)/2, where the width is the smaller of the two dimensions. For some of the studies, one or more animals had only partial data because they died early or reached a humane endpoint and were removed. The studies involved a total of 1103 control ver sus treatment comparisons.
Model-fitting and calculation of rate-based t/c measure. Figure 1 shows how the traditional T/C and rate based T/C are computed. The ratebased T/C relies on the assumption that the tumor volumes grow exponentially with time. To fit the data into this growth model, the volumes are log transformed, and linear regression is applied using Equation 1. Unfortunately, log transformation can make low volume measurements become extreme; so to prevent this problem, tumor volumes below 50 mm 3 were truncated to 50 mm 3 . Note that the exponential model is able to handle animals with missing data. For our analysis, the exponential growth rates were estimated for any animal with at least two unique measurement times.
To test the assumption of exponential growth, we plotted the log tumor volume versus time for 100 randomly selected animals ( Supplementary Fig. S1 ) and confirmed that the relationship was approximately linear in most cases. We also plotted the corresponding residuals versus the fitted values ( Supplementary Fig. S2 ) and confirmed that the residual values had no apparent systematic pattern. In addition, we computed the R 2 values for the fits among all the control group animals ( Supplementary Fig. S3 ). The R 2 values were generally quite high, with an interquartile range of 0.93-0.98.
Although the exponential growth model performed well for most animals, nonexponential growth is still possible. For treatment groups with nonexponential growth (ie, non constant growth rates), fitting the data into Equation 1 would yield the mean growth rates. Thus, the ratebased T/C could still be useful to detect differences in the mean growth rates between the groups.
bootstrapping. Different summarization methods and designs will produce different levels of precision in the result. To estimate the level of precision, we used a tech nique called bootstrapping. 15 Bootstrapping is a standard statistical practice that is used to estimate properties of a measure (such as its mean or variance) by random sampling with replacement from the original dataset. (This assumes that the original dataset is obtained from an independent and identically distributed population.) Bootstrapping thus starts with an original dataset and randomly generates multiple datasets that are similar to the original dataset. By computing the mean and standard deviation for each bootstrapped sample, the precision of the measures can be compared against each other. We used this technique to compare the precision of the different measures and show how changes in the study length and number of animals per group can affect the precision.
We performed a bootstrap analysis as follows (see Supplementary Fig. S4 for a flow chart). For each pair of control versus treatment arms, we generated 30 bootstrap samples of the data for the pair. For each animal in each boot strap sample, we truncated the low tumor volumes and per formed a leastsquares fit to Equation 1 to estimate the tumor growth rate. The mean growth rate for each group was used in Equation 3 to compute the ratebased T/C for the boot strap sample. We also computed the traditional T/C using Equation 2 without any log transformation or truncation.
comparison of study designs against each other. To quantify the variation across different bootstrap samples, we used Equation 4 to compute the Zscore for each control versus treatment comparison. We then computed the median Zscore across all the comparisons for both the traditional T/C and ratebased T/C. The number of animals per group in the bootstrap samples was varied from 4 to 10 animals, and the CanCer InformatICs 2014:13(s4) Zscore calculations were redone. Two different study lengths were considered by truncating the data at either 14 or 21 days. The impact on the Zscore was then examined.
We were interested in understanding the implications of different study designs on the overall cost. A detailed financial model was constructed by us, based on inhouse data, to eval uate each step of a xenograft study in terms of manpower and consumable costs. To compare relative costs of studies against each other, we normalized the studies to the most expensive study, setting the cost of that to 100%.
We also performed power calculations for the ratebased T/C using 14 days of data. The Zscores computed by boot strapping were used in Equation 5 to estimate the power of each comparison. Equation 5 assumes that the distribution of the log of the ratebased T/C across the bootstrap samples is approximately normal, so we verified this assumption using normal QQ plots (see Supplementary Fig. S5 ). Next, among the comparisons for which the ratebased T/C was below 0.4, the power estimates were averaged. The threshold of 0.4 was chosen because it is a common cutoff to determine if the anti tumor activity is sufficient to be of practical significance. The result was an estimate of the average power to detect a rate based T/C below 0.4. The average power was estimated for various sample sizes. results Figure 2 shows examples of the ratebased and traditional T/C computed for two different studies. The calculations were done using the data up to days 7, 14, or 21. The traditional T/C tends to decrease as the study length increases, since the groups become more separated with time. In contrast, the ratebased T/C is normalized to a fixed day, so it is more stable with respect to study length. Table 1 shows the estimated power versus the number of animals per group. For xenograft studies that are being con ducted for the purposes of assessing robust biological activity (typically assessed as a T/C below 0.4), the ratebased T/C is powered at between 99% (for 10 animals) and 93% (for 4 ani mals). While this runs counter to the perception of xenograft studies being noisy, the basic point is one that is familiar to many researchers in the field, namely that robust biological activity in a xenograft study can be quite reliable. To place the power of these studies in context, it is worth noting that a power of 80% is typically considered adequate for hypothesis testing. 19 Figure 3 shows the median Zscore versus the study cost for several different scenarios. A Zscore of 1.96 corre sponds to a 5% chance of observing a result as a consequence of chance (α = 0.05). It is thus worth noting that a xenograft study run with 10 mice for 21 days provides a Z score of 4.63, corresponding to a 0.0004% chance of observing the result purely by chance (α = 0.000004). Figure 3A shows that the ratebased T/C has a higher median Zscore and is thus more precise than the traditional T/C for the same group size. While the gain from the rate based T/C is small, it is statistically significant, with a Pvalue of 2 × 10 -16 found by using the nonparametric sign test to com pare the two measures with 10 animals per group. This small change also allows a reduction in study sizes, as switching to the ratebased T/C allows a reduction from 10 animals to 7 animals with no reduction in Zscore. Note that using the ratebased T/C yields a Zscore of 2.95 for a study with four mice at 21 days (α cutoff of 0.003). Figure 3B shows that for a given sample size, 14day studies are almost identical in precision to 21day studies (Zscore of 3.19 for five mice at 14 days versus 3.28 for five mice at 21 days). However, the 14day studies are less expensive, and also permit a higher study throughput, if that is desired. Supplementary Figure S6 shows the isoZ curves for a range of study sizes and study lengths (the calculation is described in the Supplementary File) . Each line on these plots connects points with the same Zscore. For a Zscore of 3, study lengths of 10-21 days are essentially equivalent in terms of the study size. As the study length is reduced below 10 days, larger group sizes are required to achieve the same Zscore.
We acknowledge that the final choice of sample size is somewhat subjective, as this will also depend on the study objectives in any given situation. Also, the benefit of increased power is hard to quantify in financial terms, so one cannot easily compare with the cost of an increased sample size. In our case, we believe that a sample size of six animals per group, with a power of 0.96, is reasonable for routine com pound screening.
discussion
The ratebased T/C has several advantages over the traditional T/C measure, as listed in Table 2 . The ratebased T/C uses all available data, while the traditional T/C uses data from only a single day. Thus, the ratebased T/C is able to account for random differences in the initial volume. In addition, fitting all the data reduces the effect of measurement noise and allows the ratebased T/C estimates to be more precise.
In addition to making full use of the data, the ratebased T/C has an advantage in that the measure does not strongly depend on the study length. The traditional T/C, however, is sensitive to the study length because longer studies show a greater divergence in the volumes of the groups. As the growth rate of the control arm usually determines the length of a xenograft study for a given model, comparing T/C ratios between xenograft models usually results in comparisons between studies of different lengths. For such experiments, the ratebased T/C would allow a more meaningful compar ison, because the analysis could be normalized to the same fixed time, regardless of the actual study lengths.
In xenograft studies, animals are often sacrificed for humane reasons, such as high tumor volume or excessive drug toxicity. As a result, these animals have shorter time series pro files compared with the other animals in the same study. We acknowledge that as with the traditional T/C, the ratebased T/C also suffers from a reduction in precision when animals are removed early. With the ratebased T/C, the growth rates for the sacrificed animals are still estimated and used to Table 1 . Mean power versus the number of animals per group. A and B) . the traditional T/C and the rate-based T/C were computed using data up to days 7, 14, or 21.
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CanCer InformatICs 2014:13(s4) calculate the overall effect size. The estimated growth rates for these animals will tend to have less precision compared with animals that were not sacrificed early. Therefore, early animal sacrifices will reduce the precision of the overall ratebased T/C estimate. However, we expect this reduction in preci sion to be small in most cases because sacrifices usually occur toward the end of the study, when the tumor sizes become large and drug toxicity effects accumulate. In such cases, measurements should be available for most of the time points, so the growth rate for a sacrificed animal can still be estimated accurately. We do not expect early sacrifices to cause substan tial bias in the ratebased T/C because the sacrificed animals are still included in the analysis. Although our data showed that the simple exponential model used for the ratebased T/C worked well in most cases, it is possible for tumors to grow at a nonconstant rate in some cases. In particular, larger tumors may have slower growth rates (because of oxygen perfusion and nutrient limitations) or may sometimes cavitate (as the poorly vascularized center of a large tumor turns necrotic and collapses). This could bias the biological activity assessment with both the traditional T/C and ratebased T/C, as the smaller treated tumors do not experience these effects to the same extent. However, we expect the ratebased T/C to be less affected than the tradi tional T/C because the ratebased analysis includes data from earlier time points, before the growth rate slows. Even when the growth rates vary over time, the ratebased T/C analysis is still meaningful because it measures differences in the average growth rate between groups.
A limitation of the ratebased T/C shares with the tradi tional T/C in that the scale is not particularly intuitive. In par ticular, the scale does not have a fixed level that corresponds to stasis. For example, with a slow growing tumor model, a T/C of 0.3 may correspond to tumor regression, but in a fast growing tumor model, a T/C of 0.3 may only correspond to reduced growth. Using the growth rate ratio of treated versus control would eliminate this problem. For example, we could define the growth rate inhibition as a measure of biological activity equal to (1-(growth rate of treatment group)/(growth rate of control group)) × 100%. For this measure, a value of 0% would indicate that the treatment has no effect, a value of 100% would indicate stasis, and a value above 100% would indicate tumor regression.
To help scientists analyze their tumor xenograft data, we created an Excel spreadsheet that computes the ratebased T/C. The spreadsheet is available as a Supplementary File, and its details are described there.
The bootstrap approach presented in this paper allows us to estimate the uncertainty in our efficacy measures in an unbiased manner. In contrast, if we had instead used uncer tainty estimates that relied on assumptions specific to each biological activity measure, it would have favored measures that made conservative estimates of the uncertainty. The bootstrap approach is also preferable to simulation studies. In particular, simulation studies require assumptions about the data, so simulation would favor biological activity measures that were based on similar assumptions.
We acknowledge that other research facilities will have different amounts of measurement variability and different cost structures, so the results may be different across sites. However, we expect the ratebased T/C to outperform the traditional T/C regardless of where the data are generated because the ratebased T/C uses the data more efficiently. The recommended study length and sample size may depend on the facility, but the bootstrap approach we presented here should allow other researchers to optimize their own inhouse studies. For our studies, as we have pointed out here, the use of 10 animals in 21day studies resulted in a 99% power to detect a T/C of 0.4 and a Zscore of 4.63 (α = 0.000004). In this context, analysis based on historical data was useful to us as it suggested ways in which to rationally optimize study design without compromising experimental rigor. Although our analysis focuses on minimizing the cost for a given level of precision, cost is not necessarily the most important factor when designing a preclinical study. Other factors should be considered, such as the simplicity of the experimental design, the total time required to prepare and complete the study, laboratory space constraints, and the like lihood that the preclinical study will be predictive of future clinical results.
While our analysis recommended reducing the study length, we caution the reader that longterm studies are still necessary in some cases. In particular, certain drug side effects may not be observable in shorter studies. Since xenograft studies often have a secondary goal to provide tolerability data, researchers should consider this factor when deciding the study length. In addition, a reduction in the tumor growth rate may not be observable in a shorter trial if the drug has a delayed effect. If we expect a drug to have a delayed effect based on the mechanism of action, then a short study would not be suitable. In practice, shorter studies could be recom mended for screening, while longer studies could be used for confirmation.
In summary, our work presents a simple, alternative met ric for tumor xenograft studies, based on the growth rates of control and treated tumors. We also demonstrate that this metric is capable of providing equivalent statistical power with fewer animals and shorter study lengths.
Major Findings
The novel measure of antitumor activity proposed here, the ratebased T/C, is more efficient than the traditional T/C, requiring fewer animals to achieve the same power. We also find that 14day studies are more cost efficient than 21day studies, and that studies with six animals per group have suf ficient power.
Not all research facilities have the same level of variabil ity and operating costs, so the results may differ across sites. However, we expect the ratebased T/C to outperform the tra ditional T/C regardless of where the study is performed because the ratebased T/C makes more efficient use of the data. The optimal study length and animal number will depend on the variability and cost associated with each site, but our meth odology should allow other researchers to optimize their own studies. Overall, our results help investigators reduce the size and duration of xenograft biological activity studies without compromising statistical power.
